Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001240075 | SCV001412996 | uncertain significance | Zellweger spectrum disorders | 2022-02-03 | criteria provided, single submitter | clinical testing | This sequence change replaces cysteine, which is neutral and slightly polar, with arginine, which is basic and polar, at codon 1102 of the PEX1 protein (p.Cys1102Arg). This variant is present in population databases (rs752475812, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with PEX1-related conditions. ClinVar contains an entry for this variant (Variation ID: 965586). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt PEX1 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Mayo Clinic Laboratories, |
RCV003481014 | SCV004224037 | uncertain significance | not provided | 2022-12-08 | criteria provided, single submitter | clinical testing | PM2 |
Ambry Genetics | RCV005385006 | SCV006043258 | uncertain significance | Inborn genetic diseases | 2025-01-18 | criteria provided, single submitter | clinical testing | The c.3304T>C (p.C1102R) alteration is located in exon 21 (coding exon 21) of the PEX1 gene. This alteration results from a T to C substitution at nucleotide position 3304, causing the cysteine (C) at amino acid position 1102 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001240075 | SCV002076815 | uncertain significance | Zellweger spectrum disorders | 2018-07-28 | no assertion criteria provided | clinical testing |